SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 78,400
-600 (-0.76%)
At close: Aug 3, 2026
SK Biopharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, SK Biopharmaceuticals stock has a consensus rating of "Buy" and an average price target of ₩134,500. The average 1-year stock price forecast is 71.56% higher than the current stock price, while the lowest is ₩74,000 (-5.61%) and the highest is ₩160,000 (+104.08%).
Price Target: ₩134,500 (+71.56%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for SK Biopharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 7 | 7 | 5 | 5 |
| Buy | 4 | 4 | 4 | 3 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 14 | 14 | 13 | 12 | 10 | 11 |
Financial Forecast
Revenue This Year
955.08B
from 706.74B
Increased by 35.14%
Revenue Next Year
1.13T
from 955.08B
Increased by 18.14%
EPS This Year
3.91K
from 3.41K
Increased by 14.83%
EPS Next Year
4.94K
from 3.91K
Increased by 26.12%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is KRW.